COMPASS Pathways (5Y6) Stock Forecast & Price Target

6 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

5Y6 Analyst Ratings

Strong Buy

13 Buy

1 Hold

0 Sell

Based on 14 analysts giving stock ratings to

COMPASS

Pathways

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

5Y6 Stock 12 Month Forecast

Average Price Target

€20.89

▲(121.02% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is €20.89 with a high forecast of €56.40 and a low forecast of €11.28. The average price target represents a 121.02% change from the last price of €9.45.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","57":"€57","15.75":"€15.75","29.5":"€29.5","43.25":"€43.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56.40055135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€56.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.88679758785715,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€20.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.28011027,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€11.28</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,15.75,29.5,43.25,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.65,13.246196257692308,16.842392515384617,20.438588773076923,24.034785030769232,27.63098128846154,31.227177546153847,34.82337380384615,38.419570061538465,42.01576631923077,45.61196257692308,49.20815883461538,52.804355092307695,{"y":56.40055135,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.65,10.51436904521978,11.378738090439562,12.243107135659342,13.107476180879123,13.971845226098903,14.836214271318685,15.700583316538465,16.564952361758245,17.429321406978026,18.293690452197808,19.15805949741759,20.022428542637368,{"y":20.88679758785715,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.65,9.775393097692309,9.900786195384615,10.026179293076924,10.15157239076923,10.276965488461538,10.402358586153847,10.527751683846153,10.653144781538462,10.778537879230768,10.903930976923077,11.029324074615385,11.154717172307691,{"y":11.28011027,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.62,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.779,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.45,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.76,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.9,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.65,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€56.40

Average Price Target€20.89

Lowest Price Target€11.28

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Paul Matteis

Stifel Nicolaus

€18.22

Buy

92.82%

Upside

Reiterated

08/13/26

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Spyre Therapeutics (NASDAQ: SYRE) and COMPASS Pathways (NASDAQ: CMPS)

Sumant Kulkarni

Canaccord Genuity

€17.35

Buy

83.64%

Upside

Reiterated

08/13/26

Canaccord Genuity Keeps Their Buy Rating on COMPASS Pathways (CMPS)

Gavin Clark-Gartner

Evercore ISI

€18.22

Buy

92.82%

Upside

Reiterated

08/10/26

COMPASS Pathways (CMPS) Gets a Buy from Evercore ISI

Patrick Trucchio

H.C. Wainwright

€60.74→€56.4

Buy

496.83%

Upside

Reiterated

08/07/26

Compass Pathways price target lowered to $65 from $70 at H.C. WainwrightCompass Pathways price target lowered to $65 from $70 at H.C. Wainwright

Michael Okunewitch

Maxim Group

€17.35

Buy

83.64%

Upside

Reiterated

08/07/26

Analysts' Top Healthcare Picks: COMPASS Pathways (CMPS), Trulieve Cannabis (TRLV)

Madison Elsaadi

B. Riley Securities

€14.75→€19.09

Buy

102.00%

Upside

Reiterated

08/06/26

Compass Pathways price target raised to $22 from $17 at B. RileyCompass Pathways price target raised to $22 from $17 at B. Riley

Judah Frommer

Morgan Stanley

€14.75→€15.62

Buy

65.28%

Upside

Reiterated

08/06/26

Analysts Offer Insights on Healthcare Companies: Qiagen (NYSE: QGEN), COMPASS Pathways (NASDAQ: CMPS) and Pfizer (NYSE: PFE)

Ritu Baral

TD Cowen

€25.16

Buy

166.28%

Upside

Reiterated

08/05/26

Ritu Baral Reiterates Buy on COMPASS Pathways as COMP360 Advances Toward 2027 Launch with Strong Cash Runway

Leonid Timashev

RBC Capital

€19.09→€18.22

Buy

92.82%

Upside

Assigned

08/05/26

Compass Pathways price target lowered to $21 from $22 at RBC CapitalCompass Pathways price target lowered to $21 from $22 at RBC Capital

Francois Brisebois

LifeSci Capital

€20.82

Buy

120.37%

Upside

Reiterated

08/05/26

Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS), Geron (NASDAQ: GERN) and Azenta (NASDAQ: AZTA)

Benjamin Burnett

Wells Fargo

€11.28

Hold

19.37%

Upside

Reiterated

08/05/26

Wells Fargo Sticks to Its Hold Rating for COMPASS Pathways (CMPS)

Rudy Li

Wolfe Research

€15.62

Buy

65.28%

Upside

Reiterated

07/07/26

Analyst Reaffirms Buy on CMPS, Viewing Post-Data Pullback as Entry Opportunity Ahead of 1H27 Launch

Jay Olson

Oppenheimer

€17.35

Buy

83.64%

Upside

Reiterated

07/07/26

Compass Pathways data strengthens launch prospects, says OppenheimerCompass Pathways data strengthens launch prospects, says Oppenheimer

Thomas Shrader

BTIG

€12.15→€21.69

Buy

129.55%

Upside

Reiterated

07/07/26

Analysts Conflicted on These Healthcare Names: Cooper Co (NASDAQ: COO), Tvardi Therapeutics (NASDAQ: TVRD) and COMPASS Pathways (NASDAQ: CMPS)

Andrew Tsai

Jefferies

€15.62

Buy

65.28%

Upside

Reiterated

05/14/26

Jefferies Remains a Buy on COMPASS Pathways (CMPS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Paul Matteis

Stifel Nicolaus

€18.22

Buy

92.82%

Upside

Reiterated

08/13/26

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Spyre Therapeutics (NASDAQ: SYRE) and COMPASS Pathways (NASDAQ: CMPS)

Sumant Kulkarni

Canaccord Genuity

€17.35

Buy

83.64%

Upside

Reiterated

08/13/26

Canaccord Genuity Keeps Their Buy Rating on COMPASS Pathways (CMPS)

Gavin Clark-Gartner

Evercore ISI

€18.22

Buy

92.82%

Upside

Reiterated

08/10/26

COMPASS Pathways (CMPS) Gets a Buy from Evercore ISI

Patrick Trucchio

H.C. Wainwright

€60.74→€56.4

Buy

496.83%

Upside

Reiterated

08/07/26

Compass Pathways price target lowered to $65 from $70 at H.C. WainwrightCompass Pathways price target lowered to $65 from $70 at H.C. Wainwright

Michael Okunewitch

Maxim Group

€17.35

Buy

83.64%

Upside

Reiterated

08/07/26

Analysts' Top Healthcare Picks: COMPASS Pathways (CMPS), Trulieve Cannabis (TRLV)

Madison Elsaadi

B. Riley Securities

€14.75→€19.09

Buy

102.00%

Upside

Reiterated

08/06/26

Compass Pathways price target raised to $22 from $17 at B. RileyCompass Pathways price target raised to $22 from $17 at B. Riley

Judah Frommer

Morgan Stanley

€14.75→€15.62

Buy

65.28%

Upside

Reiterated

08/06/26

Analysts Offer Insights on Healthcare Companies: Qiagen (NYSE: QGEN), COMPASS Pathways (NASDAQ: CMPS) and Pfizer (NYSE: PFE)

Ritu Baral

TD Cowen

€25.16

Buy

166.28%

Upside

Reiterated

08/05/26

Ritu Baral Reiterates Buy on COMPASS Pathways as COMP360 Advances Toward 2027 Launch with Strong Cash Runway

Leonid Timashev

RBC Capital

€19.09→€18.22

Buy

92.82%

Upside

Assigned

08/05/26

Compass Pathways price target lowered to $21 from $22 at RBC CapitalCompass Pathways price target lowered to $21 from $22 at RBC Capital

Francois Brisebois

LifeSci Capital

€20.82

Buy

120.37%

Upside

Reiterated

08/05/26

Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS), Geron (NASDAQ: GERN) and Azenta (NASDAQ: AZTA)

Benjamin Burnett

Wells Fargo

€11.28

Hold

19.37%

Upside

Reiterated

08/05/26

Wells Fargo Sticks to Its Hold Rating for COMPASS Pathways (CMPS)

Rudy Li

Wolfe Research

€15.62

Buy

65.28%

Upside

Reiterated

07/07/26

Analyst Reaffirms Buy on CMPS, Viewing Post-Data Pullback as Entry Opportunity Ahead of 1H27 Launch

Jay Olson

Oppenheimer

€17.35

Buy

83.64%

Upside

Reiterated

07/07/26

Compass Pathways data strengthens launch prospects, says OppenheimerCompass Pathways data strengthens launch prospects, says Oppenheimer

Thomas Shrader

BTIG

€12.15→€21.69

Buy

129.55%

Upside

Reiterated

07/07/26

Analysts Conflicted on These Healthcare Names: Cooper Co (NASDAQ: COO), Tvardi Therapeutics (NASDAQ: TVRD) and COMPASS Pathways (NASDAQ: CMPS)

Andrew Tsai

Jefferies

€15.62

Buy

65.28%

Upside

Reiterated

05/14/26

Jefferies Remains a Buy on COMPASS Pathways (CMPS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering COMPASS Pathways

3 Months

Michael OkunewitchMaxim Group

Success Rate

9/12 ratings generated profit

Average Return

+33.07%

Copying Michael Okunewitch's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +33.07% per trade.

1 Year

Patrick TrucchioH.C. Wainwright

Success Rate

17/19 ratings generated profit

Average Return

+94.05%

Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 89.47% of your transactions generating a profit, with an average return of +94.05% per trade.

2 Years

Michael OkunewitchMaxim Group

Success Rate

12/12 ratings generated profit

Average Return

+157.79%

Copying Michael Okunewitch's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +157.79% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

5Y6 Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 5Y6 has received 27 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 5Y6 average Analyst price target in the past 3 months is 20.89.

Each month's total comprises the sum of three months' worth of ratings.

5Y6 Financial Forecast

5Y6 Earnings Forecast

Next quarter’s earnings estimate for 5Y6 is -€0.31 with a range of -€0.37 to -€0.05. The previous quarter’s EPS was -€1.63. 5Y6 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 5Y6 has Performed in-line its overall industry.

No data currently available

5Y6 Sales Forecast

Next quarter’s sales forecast for 5Y6 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 5Y6 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 5Y6 has Performed in-line its overall industry.

5Y6 Stock Forecast FAQ

What is DE:5Y6’s average 12-month price target, according to analysts?

Based on analyst ratings, COMPASS Pathways’s 12-month average price target is 20.89.

What is DE:5Y6’s upside potential, based on the analysts’ average price target?

COMPASS Pathways has 121.02% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is COMPASS Pathways a Buy, Sell or Hold?

COMPASS Pathways has a consensus rating of Strong Buy, which is based on 13 buy ratings, 1 hold ratings and 0 sell ratings.

What is COMPASS Pathways’s share price target?

The average share price target for COMPASS Pathways is 20.89. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €56.40 ,and the lowest forecast is €11.28. The average share price target represents 121.02% Increase from the current price of €9.45.

What do analysts say about COMPASS Pathways?

COMPASS Pathways’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of COMPASS Pathways?

To buy shares of DE:5Y6, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

COMPASS Pathways (5Y6) Stock Forecast & Price Target

5Y6 Analyst Ratings

5Y6 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering COMPASS Pathways

5Y6 Analyst Recommendation Trends

5Y6 Financial Forecast

5Y6 Earnings Forecast

5Y6 Sales Forecast

5Y6 Stock Forecast FAQ

Detailed List of Analyst Forecasts